Mayo Clinic researchers develop first salivary gland regenerative biobank to combat chronic dry mouth

Rybrevant Faspro combination demonstrates 77% ORR in first-line treatment of advanced head and neck cancer, phase II study finds

First-line subcutaneous Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) plus a PD-1 inhibitor and fixed-duration carboplatin chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma showeddeep and durable responses, according to the results from Cohort 5 of the phase Ib/II OrigAMI-4 study.

October 30, 2026

Vol.52 No.40

Clinical Roundup

Earlier survivorship care linked to lower risk of head and neck cancer recurrence and death

Beginning survivorship care for head and neck cancer patients earlier is linked to better survival and lower recurrence, according to the findings of a study led by researchers at the University of Pittsburgh.

October 30, 2026

Vol.52 No.40

Clinical Roundup

Researchers suggest tile-based radiation therapy as standard of care to lower risk of recurrence in brain metastases

A multi-center clinical trial led by researchers at The University of Texas MD Anderson Cancer Center has found that implanting collagen tiles during brain surgery to deliver targeted radiation therapy dramatically improved tumor control, lowered the risk of recurrence, and improved overall survival compared to current standard of care for patients with newly diagnosed brain metastases in need of surgical resection.

October 23, 2026

Vol.52 No.39

Clinical Roundup

Researchers uncovers immune driver of radiation-related lung injury, City of Hope-led preclinical study finds

Researchers at City of Hope have uncovered an immune pathway that may contribute to radiation-related lung damage and have identified a potential strategy to block it. The insights from the preclinical study could lead to treatments that prevent radiation from harming healthy lung tissue and improve patients’ quality of life.

October 23, 2026

Vol.52 No.39

Clinical Roundup

Johns Hopkins investigators identify a metabolic weak point in exhausted immune cells in head and neck cancer

Immune cells can reach head and neck tumors, but once there, many stop functioning. This helps explain why immunotherapy with immune checkpoint inhibitors—which have transformed treatment for some cancers—benefit only 17% to 23% of patients with head and neck squamous cell carcinoma.

October 02, 2026

Vol.52 No.36

Clinical Roundup

ASTRO updates guideline on radiation therapy for pancreatic cancer

An updated clinical guideline from the American Society for Radiation Oncology provides evidence-based recommendations on the use of radiation therapy to treat adult patients with pancreatic cancer.

September 11, 2026

Vol.52 No.33

Mayo Clinic researchers develop first salivary gland regenerative biobank to combat chronic dry mouth

YOU MAY BE INTERESTED IN

Rybrevant Faspro combination demonstrates 77% ORR in first-line treatment of advanced head and neck cancer, phase II study finds

Earlier survivorship care linked to lower risk of head and neck cancer recurrence and death

Researchers suggest tile-based radiation therapy as standard of care to lower risk of recurrence in brain metastases

Researchers uncovers immune driver of radiation-related lung injury, City of Hope-led preclinical study finds

Johns Hopkins investigators identify a metabolic weak point in exhausted immune cells in head and neck cancer

ASTRO updates guideline on radiation therapy for pancreatic cancer

Renew today!

Subscriber content

Never miss an issue!

Login